NERX Neorx (MM)

SEATTLE, May 8 /PRNewswire-FirstCall/ -- NeoRx Corporation (NASDAQ:NERX) today announced that Jerry McMahon, Ph.D., chairman and CEO, will present at two upcoming conferences in May: Rodman & Renshaw 3rd Annual Global Healthcare Conference on Monday, May 15, at 5:05 p.m. Central European time in Monaco (8:05 a.m. Pacific Time). Bank of America Health Care Conference 2006 on Thursday, May 18, at 12:40 p.m. Pacific Time in Las Vegas. Dr. McMahon will provide an update on the clinical development program for picoplatin, the Company's lead product and a new generation platinum therapy that provides a differentiated spectrum of activity, reduced reactivity and an improved safety profile. Currently, picoplatin is being studied in a Phase 2 clinical trial in patients with small cell lung cancer at clinical sites in North America and Eastern Europe. A live audio webcast of each presentation will be available on the "Events and Webcasts" page of the "Investors" section of the NeoRx web site at: http://phx.corporate-ir.net/phoenix.zhtml?c=76446&p=irol-presentations. About NeoRx NeoRx is a specialty pharmaceutical company dedicated to the discovery, development and commercialization of oncology drugs that impact the lives of individuals afflicted with cancer. The Company currently is focusing its development efforts on picoplatin, a new generation platinum therapy that provides a differentiated spectrum of activity, reduced reactivity and an improved safety profile. An intravenous chemotherapeutic, picoplatin is designed to overcome multiple mechanisms of platinum-based chemoresistance. NeoRx also is collaborating with the Scripps Florida Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors for the treatment of cancer. For more information, visit http://www.neorx.com/. This release contains forward-looking statements, including statements regarding the Company's business model, drug development programs and clinical trial plans. The Company's actual results may differ materially from those indicated in these forward looking statements based on a number of factors, including anticipated operating losses, uncertainties associated with research, development, testing and related regulatory approvals, future capital needs and uncertainty of additional financing, competition, uncertainties associated with intellectual property, dependence on third-party manufacturers, suppliers and collaborators, lack of sales and marketing experience, loss of key personnel, uncertainties associated with market acceptance, technology change and government regulation, and the other risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission, including NeoRx's Annual Report on Form 10-K for the year ended December 31, 2005. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events. DATASOURCE: NeoRx Corporation CONTACT: Julie Rathbun, Corporate Communications of NeoRx Corporation, +1-206-286-2517, or Web site: http://www.neorx.com/

Copyright